Callejas Rubio, José LuisLuna Del Castillo, Juan de Diosde la Hera Fernández, JavierGuirao Arrabal, EmilioColmenero Ruiz, ManuelOrtego Centeno, Norberto2023-02-092023-02-092020-05-27http://hdl.handle.net/10668/15731Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19. We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable. In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival. The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.enCoronavirus COVID-19Cytokine release synddromeHemofagocíticoHemophagocyticSíndrome de liberación de citocinasAdrenal Cortex HormonesAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBetacoronavirusCOVID-19Coronavirus InfectionsCytokine Release SyndromeDrug Administration ScheduleFemaleHumansIntubation, IntratrachealKaplan-Meier EstimateMaleMiddle AgedPandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2research article32532461open access10.1016/j.medcli.2020.04.0181578-8989PMC7250763https://doi.org/10.1016/j.medcli.2020.04.018https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250763/pdf